Heparine Sodique Panpharma (Heparin Sodium)

Heparine Sodique Panpharma is indicated for several clinical situations where anticoagulation is required to reduce the risk of clot formation.

• Prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Prophylaxis of thromboembolic events in patients undergoing orthopedic, abdominal, or vascular surgery.
• Management of acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction.
• Anticoagulation during extracorporeal circulation procedures such as cardiopulmonary bypass or hemodialysis.
• Use in patients with atrial fibrillation when rapid anticoagulation is needed.

The safety profile of Heparine Sodique Panpharma reflects the typical effects observed with heparin therapy.

Common

• Minor bleeding at the injection site or from mucous membranes such as nosebleeds, which usually resolves without intervention.
• Small bruising or hematoma formation around the infusion area, often noticeable as a localized discoloration.
• Transient elevation of liver enzymes without accompanying clinical symptoms, typically returning to baseline after continued therapy.

Serious

• Major hemorrhage, including life‑threatening gastrointestinal or intracranial bleeding, requiring immediate medical attention.
• Heparin‑induced thrombocytopenia (HIT), an immune‑mediated reaction causing a rapid decline in platelet count and paradoxical clotting.
• Allergic reactions ranging from mild urticaria to severe anaphylaxis, which may necessitate discontinuation of therapy.

Before initiating Heparine Sodique Panpharma, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Assess baseline coagulation parameters (e.g., aPTT, platelet count) and repeat monitoring during treatment.
• Use caution in patients with a history of heparin‑induced thrombocytopenia or known hypersensitivity to heparin.
• Adjust dose or avoid use in individuals with active bleeding, recent major surgery, or uncontrolled hypertension.
• Consider renal or hepatic impairment, as altered clearance may affect anticoagulant response.
• Avoid concurrent use with other anticoagulants or antiplatelet agents unless specifically indicated.
• Counsel pregnant or nursing women that safety data are limited and decisions should be individualized.

Heparine Sodique Panpharma may interact with several medications, influencing anticoagulant effect or bleeding risk.

Avoid

• Concurrent use with other parenteral anticoagulants (e.g., direct thrombin inhibitors) due to additive bleeding risk.
• Simultaneous administration of fibrinolytic agents such as alteplase or streptokinase, which can markedly increase hemorrhage.

Use with caution

• Co‑administration with antiplatelet drugs (e.g., aspirin, clopidogrel) may enhance bleeding tendency; monitor closely.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) and selective COX‑2 inhibitors can impair platelet function and should be used judiciously.
• Certain antibiotics (e.g., vancomycin, rifampin) may alter heparin binding and affect anticoagulant activity.
• High‑dose corticosteroids may increase gastrointestinal bleeding risk when combined with heparin therapy.